Analysis of the UALCAN data indicated that there have no obvious differences in the ATAD3A level among different patient races, sexes, body weights, smoking statuses, or lymph node metastases, as shown in Figure 1A–E. Here, ATAD3A is linked to metastatic malignant neoplasm in the lymph nodes.